IGF1 and hepatocellular carcinoma: Unlike our nude mice with subcutaneously implanted HCC xenografts who maintain intact livers capable of secreting physiologic levels of IGF-I, patients with HCC encounter deterioration in liver reserve and function during disease progression, which leads to significant reduction in circulating IGF-I (28–30).